MDxHealth SA Stock Euronext Bruxelles
Stocks
MDXH
BE0974461940
Biotechnology & Medical Research
| Market Cap | 58.82M 68.67M 55.04M 50.38M 94.55M 6.57B 95.8M 650M 254M 3.3B 258M 252M 10.92B | P/E 2026 * |
-1.4x | P/E 2027 * | -2.53x |
|---|---|---|---|---|---|
| Enterprise Value | 180M 210M 168M 154M 289M 20.06B 292M 1.99B 774M 10.08B 787M 770M 33.33B | EV / Sales 2026 * |
1.87x | EV / Sales 2027 * | 1.81x |
| Free-Float |
77.86% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: MDxHealth SA
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 18/02/2019 | |
Ron Kalfus
DFI | Director of Finance/CFO | 52 | 22/07/2019 |
Miriam Reyes
COO | Chief Operating Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Hilde Windels
BRD | Director/Board Member | 61 | 01/11/2017 |
Koen Hoffman
CHM | Chairman | 58 | 01/01/2018 |
| Director/Board Member | 64 | 18/02/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -2.58% | - | - | 68.7M | |
| +1.09% | +5.26% | +4.44% | +26.03% | 51.22B | |
| -2.17% | +2.18% | +470.60% | +596.87% | 45.38B | |
| +2.13% | +8.62% | +20.22% | +92.45% | 41.97B | |
| +0.67% | +8.84% | +38.94% | +20.16% | 42.15B | |
| -0.93% | -4.80% | +17.39% | +46.60% | 31.95B | |
| +0.24% | +2.77% | - | - | 16.73B | |
| +2.09% | +8.17% | +38.03% | +154.39% | 17.1B | |
| +0.03% | +3.41% | +7.12% | +35.49% | 14.76B | |
| +1.38% | +5.54% | +91.25% | +47.11% | 13.91B | |
| Average | +0.43% | +3.19% | +86.00% | +127.39% | 30.58B | |
| Weighted average by Cap. | +0.35% | +3.13% | +103.14% | +148.81% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 96.12M 112M 89.94M 82.33M 155M 10.74B 157M 1.06B 414M 5.39B 421M 412M 17.84B | 109M 127M 102M 93.22M 175M 12.16B 177M 1.2B 469M 6.11B 477M 467M 20.2B |
| Net income | -29.64M -34.6M -27.73M -25.39M -47.64M -3.31B -48.27M -328M -128M -1.66B -130M -127M -5.5B | -18.12M -21.15M -16.95M -15.52M -29.13M -2.02B -29.51M -200M -78.11M -1.02B -79.43M -77.7M -3.36B |
| Net Debt | 121M 141M 113M 103M 194M 13.49B 197M 1.33B 521M 6.78B 529M 518M 22.41B | 139M 162M 130M 119M 223M 15.49B 226M 1.53B 598M 7.78B 608M 595M 25.74B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
